TABLE 2.

Acute Asthma Presentation, ED Course, and 2-Week Follow-up of US Children, According to Race/Ethnicity

Black (n = 679)Hispanic (n = 256)White (n = 160)P Value
Presentation
 Duration of symptoms <24 h (%)666463.79
 Severe symptoms (%) *636768.42
ED course
 Pulmonary index score (mean ± SD)*4.4 ± 2.44.3 ± 2.34.1 ± 2.4.42
 Severity score (%) *.59
  1 (mild)242326
  2272924
  3262932
  4 (severe)221918
No. of inhaled β-agonists in first hour (mean ± SD)1.8 ± 1.21.6 ± 0.81.9 ± 1.1.03
No. of inhaled β-agonists over ED stay (mean ± SD)3.2 ± 2.62.8 ± 1.73.2 ± 2.6.03
Given steroid treatment (%)807777.50
ED length of stay (min; median [IQR])150 (110–205)140 (110–205)150 (115–219).64
Sent home on systemic corticosteroids (%) 787878.98
Sent home on inhaled corticosteroids (new; %) 446.84
Admitted (%)242126.49
Comorbid medical condition366.06
2-wk follow-up
 Hospital length of stay (d; median [IQR])2 (2–3)2 (2–3)2 (2–3).57
 Relapse within 2 wk of ED visit (%) §8138.11
 Days to relapse event (median [IQR])4 (1–8)3 (1–6)2 (1–7).58
 Ongoing exacerbation (%)*10119.72
 Relapse event or ongoing exacerbation (%)172214.10
  • * See Methods for details.

  • Restricted to patients sent home from ED (n = 851).

  • Restricted to patients with 2-week follow-up (n = 966).

  • § Relapse event based on patient reporting a “worsening of asthma symptoms” that led to an urgent care visit.